PepGen (PepGen) Cash-to-Debt : 8.86 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PepGen Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PepGen's cash to debt ratio for the quarter that ended in Mar. 2024 was 8.86.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PepGen could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for PepGen's Cash-to-Debt or its related term are showing as below:

PEPG' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.49 Med: 8.86 Max: No Debt
Current: 8.86

During the past 4 years, PepGen's highest Cash to Debt Ratio was No Debt. The lowest was 5.49. And the median was 8.86.

PEPG's Cash-to-Debt is ranked better than
53.45% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs PEPG: 8.86

PepGen Cash-to-Debt Historical Data

The historical data trend for PepGen's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PepGen Cash-to-Debt Chart

PepGen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

7.41

5.49

PepGen Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial									7.58	6.88	6.34	5.49	8.86

Competitive Comparison of PepGen's Cash-to-Debt

For the Biotechnology subindustry, PepGen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PepGen's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PepGen's Cash-to-Debt falls into.

PepGen Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PepGen's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	110.407	/	(3.004	+	17.1)
	=	5.49

PepGen's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	175.223	/	(3.026	+	16.743)
	=	8.86

PepGen (NAS:PEPG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PepGen Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PepGen's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PepGen (PepGen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118

Website

https://www.pepgen.com

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Executives

James G Mcarthur	director, officer: President and CEO	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Jaya Goyal	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton	director	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C)	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michelle L Mellion	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Noel Donnelly	officer: Chief Financial Officer	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Sonia Bracegirdle	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p.	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p.	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT